Growth hormone and Prader-Willi syndrome: experience and perspective

Abstract

The initial report of Prader-Willi syndrome (PWS), published in 1956, described five major morbidities: short stature, hypotonia, obesity, hypogonadism, and cognitive delay. The clinical definition of PWS was fine-tuned over the next 3 decades; reported association with abnormalities in chromosome 15q in the 1980s led to the genetic definition in the 1990s. Human growth hormone (GH) was first purified in the 1950s, followed by increased therapeutic use of preparations purified from human pituitaries, which were emergently replaced by recombinant DNA-produced GH in 1985. Coincident developments in both fields led to trials of GH treatment for PWS and regulatory approval of GH treatment for PWS in 2000. As the only therapeutic agent with worldwide labeling for PWS, GH has shown efficacy for growth and hypotonia. Potential benefits for cognitive function and obesity have also been suggested, particularly with early treatment. A warning added in 2002 to the GH label for the PWS indication regarding use in severe obesity and severe respiratory impairment does not appear to be fully evidence-based; few other adverse effects have been observed. Delayed diagnosis and treatment of PWS continues to be a significant problem. The inclusion of PWS in newborn screening programs, a current area of research, would address the issue of late diagnosis, facilitating earlier initiation of GH treatment. Initial steps toward genetic therapy provide hope for a more complete medical treatment for this condition.

Keywords

Prader-Willi syndrome / growth hormone / obesity

References

[1] Forsyth IA.Growth hormone and prolactin--molecular and functional evolution.J Mammary Gland Biol Neoplasia2002;7:291-312

[2] Salmon WD.A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro.J Lab Clin Med1957;49:825-36

[3] Bach LA.IGF-binding proteins.J Mol Endocrinol2018;61:T11-28

[4] Conover CA.The IGF system and aging.Endocr Rev2025;46:214-23 PMCID:PMC11894535

[5] Frasier SD.Human pituitary growth hormone (hGH) therapy in growth hormone deficiency.Endocr Rev1983;4:155-70

[6] Ching J.Brief review and commentary: diagnosis of pediatric pituitary disorders.Pituitary2007;10:327-33

[7] Hunter WM.Studies on the secretion of human-pituitary-growth hormone.Br Med J1964;1:804-7 PMCID:PMC1815069

[8] Raiti S.The national hormone and pituitary program (NHPP) historical perspective.Acta Endocrinol Suppl (Copenh)1986;279:66-70

[9] Frasier SD.The not-so-good old days: working with pituitary growth hormone in North America, 1956 to 1985.J Pediatr1997;131:S1-4

[10] Blizzard RM.History of growth hormone therapy.Indian J Pediatr2012;79:87-91

[11] Cronin MJ.Pioneering recombinant growth hormone manufacturing: pounds produced per mile of height.J Pediatr1997;131:S5-7

[12] Johnson IS.The trials and tribulations of producing the first genetically engineered drug.Nat Rev Drug Discov2003;2:747-51

[13] Hintz RL.The prismatic case of Creutzfeldt-Jakob disease associated with pituitary growth hormone treatment.J Clin Endocrinol Metab1995;80:2298-301

[14] Graber EG,Wilson DM.The unfolding story of protein misfolding causing alzheimer disease in recipients of human pituitary growth hormone.J Endocr Soc2025;9:bvaf029 PMCID:PMC11860808

[15] Hintz RL.The importance of the National Cooperative Growth Study (NCGS). In: Carel J-C, Kelly PA, Christen Y, editors. Deciphering Growth. Research and Perspectives in Endocrine Interactions. Berlin, Heidelberg: Springer; 2005. p. 131-2.

[16] Allen DB.Growth promotion ethics and the challenge to resist cosmetic endocrinology.Horm Res Paediatr87:145-152

[17] Cuttler L.Growth hormone and health policy.J Clin Endocrinol Metab2010;95:3149-53 PMCID:PMC2928896

[18] Carlson GA.How an infection of sheep revealed prion mechanisms in Alzheimer’s disease and other neurodegenerative disorders.Int J Mol Sci2021;22:4861 PMCID:PMC8125442

[19] Fink J,Hackney AC.Anabolic-androgenic steroids: procurement and administration practices of doping athletes.Phys Sportsmed2019;47:10-4

[20] Prader A,Willi H. Ein syndrom von adipositas, kleinwuchs, kryptorchismusund oligophrenie nach myatonieartigem zustand im neogeborenenalter. Schweiz Med Wochenschr 1956;86:1260-1. (in German) Available from: https://scholar.google.com/scholar_lookup?&title=Ein%20Syndrom%20von%20Adipositas%2C%20Kleinwuchs%2C%20Kryptorchismus%20und%20Oligophrenie%20nach%20myatonieartigem%20Zustand%20im%20Neogeborenenalter&journal=Schweiz%20Med%20Wochenschr&volume=86&pages=1260-1261&publication_year=1956&author=Prader%2CA&author=Labhart%2CA&author=Willi%2CH (accessed on 2025-6-23)

[21] Pozzilli P.“La Monstrua Vestida”, a case of Prader-Willi syndrome.J Endocrinol Invest2005;28:199

[22] Eiholzer U.Appendix A: first published report of Prader-Willi syndrome. In: Butler MG, Lee PDK, Whitman BY, editors. Management of Prader-Willi Syndrome. 4th ed. Berlin, Heidelberg: Springer; 2022. p. 487-90.

[23] Zellweger H.Syndrome of hypotonia-hypomentia-hypogonadism-obesity (HHHO) or Prader-Willi syndrome.Am J Dis Child1968;115:588-98

[24] Ledbetter DH,Airhart SD,Keenan BS.Deletions of chromosome 15 as a cause of the Prader-Willi syndrome.N Engl J Med1981;304:325-9

[25] Butler MG.Parental origin of chromosome 15 deletion in Prader-Willi syndrome.Lancet1983;1:1285-6 PMCID:PMC5510872

[26] Nicholls RD,Butler MG,Lalande M.Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome.Nature1989;342:281-5 PMCID:PMC6706849

[27] Holm VA,Butler MG.Prader-Willi syndrome: consensus diagnostic criteria.Pediatrics1993;91:398-402

[28] Heimdörfer D,Eschlböck A.Truncated variants of MAGEL2 are involved in the etiologies of the Schaaf-Yang and Prader-Willi syndromes.Am J Hum Genet2024;111:1383-404 PMCID:PMC11267527

[29] Eiholzer U.Medical considerations. In: Butler MG, Lee PDK, Whitman BY, editors. Management of Prader-Willi Syndrome. 4th ed. Berlin, Heidelberg: Springer; 2022. p. 123-58.

[30] Sone S.Muscle histochemistry in the Prader-Willi syndrome.Brain Dev1994;16:183-8

[31] Forbes GB.A distinctive obesity: body composition provides the clue.Am J Clin Nutr1997;65:1540-1

[32] Eiholzer U,L’Allemand D.Is there growth hormone deficiency in prader-willi Syndrome?.Horm Res2000;53:44-52

[33] Eiholzer U,Molinari L.Body fat determined by skinfold measurements is elevated despite underweight in infants with Prader-Labhart-Willi syndrome.J Pediatr1999;134:222-5

[34] Scheimann AO,Lee PDK.Gastrointestinal system, obesity, and body composition. In: Butler MG, Lee PDK, Whitman BY, editors. Management of Prader-Willi Syndrome. 4th ed. Berlin, Heidelberg: Springer; 2022. p. 159-194.

[35] Beltran D.Closing round 3 about how to successfully treat obesity.MedGenMed2005;7:41 PMCID:PMC1681569

[36] Lee PD,Rountree L,Rosenfeld RG.Linear growth response to exogenous growth hormone in Prader-Willi syndrome.Am J Med Genet1987;28:865-71

[37] Angulo M,Mazur B,Vitollo PM.Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome.J Pediatr Endocrinol Metab1996;9:393-400

[38] Eiholzer U,Stutz K.Effect of 6 months of growth hormone treatment in young children with Prader-Willi syndrome.Acta Paediatr Suppl1997;423:66-8

[39] Carrel AL,Whitman BY.Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study.J Pediatr1999;134:215-21

[40] Allen DB.Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.J Pediatr Endocrinol Metab2004;17:1297-306.

[41] Carrel AL,Whitman BY.Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.J Pediatr Endocrinol Metab2001;14:1097-105

[42] Carrel AL,Whitman BY.Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.J Clin Endocrinol Metab2002;87:1581-5

[43] Butler MG,Whitman BY.Management of Prader-Willi Syndrome. 3rd ed. Berlin, Heidelberg: Springer; 2006.

[44] Carrel AL,Mogul HR.Growth hormone and Prader-Willi syndrome. In: Butler MG, Lee PDK, Whitman BY, editors. Management of Prader-Willi Syndrome, 4th ed. Berlin, Heidelberg: Springer; 2022. p. 195-216.

[45] Passone CGB,Ito SS.Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis.BMJ Paediatr Open2020;4:e000630 PMCID:PMC7213882

[46] Butler MG.Appendix C: Growth charts of individuals with Prader-Willi syndrome. In: Bulter MG, Lee PDK, Whitman BY, editors. Management of Prader-Willi Syndrome, 4th ed. Berlin, Heidelberg: Springer; 2022. p. 499-527.

[47] Lee PDK.Model for a peripheral signaling defect in Prader-Willi syndrome. In: Eiholzer U, L’Allemand D, Zipf WB, editors. Prader-Willi syndrome as a model for obesity. Basel: Karger Medical and Scientific Publishers; 2003:71-81.

[48] Butler MG,Cox DM.Growth charts for Prader-Willi Syndrome during growth hormone treatment.Clin Pediatr (Phila)2016;55:957-74 PMCID:PMC5922433

[49] Magill L,Woelfle J,Gohlke B.Early start of growth hormone is associated with positive effects on auxology and metabolism in Prader-Willi-syndrome.Orphanet J Rare Dis2020;15:283 PMCID:PMC7552493

[50] Gao Y,Dai YL,Zhou Q.Effects of early recombinant human growth hormone treatment in young Chinese children with Prader-Willi syndrome.Orphanet J Rare Dis2023;18:25 PMCID:PMC9906936

[51] Rosenberg AGW,Pellikaan K.Growth hormone treatment for adults with Prader-Willi syndrome: a meta-analysis.J Clin Endocrinol Metab2021;106:3068-91

[52] Mogul HR,Whitman BY.Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.J Clin Endocrinol Metab2008;93:1238-45

[53] Keys A,Karvonen MJ,Taylor HL.Indices of relative weight and obesity.J Chronic Dis1972;25:329-43

[54] Rubino F,Eckel RH.Definition and diagnostic criteria of clinical obesity.Lancet Diabetes Endocrinol2025;13:221-62

[55] Forbes GB.The companionship of lean and fat. In: Ellis KJ, Eastman JD, editors. Human body composition. Boston: Springer US; 1993. p. 1-14.

[56] Forbes GB.The companionship of fat and lean.Basic Life Sci1993;60:1-14

[57] Eiholzer U,van der Sluis I,Gasser T.Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy.Horm Res2000;53:200-6

[58] Lee PDK,Henson H.Body composition studies in Prader-Willi syndrome: effects of growth hormone therapy. In: Ellis KJ, Eastman JD, editors. Human Body Composition. Boston: Springer US; 1993. p. 201-5.

[59] Siemensma EP,Otten BJ,Hokken-Koelega AC.Pubarche and serum dehydroepiandrosterone sulphate levels in children with Prader-Willi syndrome.Clin Endocrinol (Oxf)2011;75:83-9

[60] Kodytková A,El-Lababidi E.Early-onset growth hormone treatment in Prader-Willi syndrome attenuates transition to severe obesity.J Pediatr Endocrinol Metab2025;38:525-32

[61] Nerli RB,Patne PB.Penile growth in response to hormone treatment in children with micropenis.Indian J Urol2013;29:288-91 PMCID:PMC3822343

[62] Zhou XY,Shen YY,Ren W.Effects of growth hormone on adult human gonads: action on reproduction and sexual function.Int J Endocrinol2023;2023:7492696 PMCID:PMC10104746

[63] Cannarella R,Sapienza S.Testicular function in postpubertal patients with growth hormone deficiency: a prospective controlled study.J Clin Transl Endocrinol2025;39:100383 PMCID:PMC11787440

[64] Jin YY.Early psychomotor development and growth hormone therapy in children with Prader-Willi syndrome: a review.Eur J Pediatr2024;183:1021-36

[65] Festen DA,Lindgren AC.Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome.Clin Endocrinol (Oxf)2008;68:919-25

[66] Böhm B,Lindgren AC.Growth hormone treatment improves vitality and behavioural issues in children with Prader-Willi syndrome.Acta Paediatr2015;104:59-67

[67] Bell JJ,Romano AA,Swinford RD.National cooperative growth study: 25 years of growth hormone data, insights, and lessons for future registries.Pediatr Endocrinol Rev2018;16:240-55

[68] Maghnie M,Geffner ME.Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort.J Clin Endocrinol Metab2022;107:3287-301 PMCID:PMC9693805

[69] Angulo M,Pietropoli A,Kelepouris N.Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® international outcome study.Int J Pediatr Endocrinol2020;2020:20 PMCID:PMC7653711

[70] Wyatt D.Lessons from the national cooperative growth study.Eur J Endocrinol2004;151:S55-9

[71] Bell J,Swinford RD,Maneatis T.Long-term safety of recombinant human growth hormone in children.J Clin Endocrinol Metab2010;95:167-77.

[72] Stochholm K.Long-term safety of growth hormone - a combined registry analysis.Clin Endocrinol (Oxf)2018;88:515-28

[73] Lämmer C,Tauber M.Growth hormone treatment in children with Prader-Willi syndrome: safety and effectiveness data from the PATRO Children study.Ther Adv Endocrinol Metab2024;15:20420188241264343 PMCID:PMC11450727

[74] Eiholzer U,L’Allemand D.Fatal outcome of sleep apnoea in PWS during the initial phase of growth hormone treatment. A case report.Horm Res2002;58 Suppl 3:24-6

[75] Lee PDK.Growth hormone and mortality in Prader-Willi syndrome.Growth Genet Horm2006;222:17-23 PMCID:PMC7213882

[76] Eiholzer U.Deaths in children with Prader-Willi syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS.Horm Res2005;63:33-9

[77] Pacoricona Alfaro DL,Ehlinger V.Causes of death in Prader-Willi syndrome: lessons from 11 years’ experience of a national reference center.Orphanet J Rare Dis2019;14:448-53 PMCID:PMC6829836

[78] Miller JL,Theriaque D,Wagner M.Sleep disordered breathing in infants with Prader-Willi syndrome during the first 6 weeks of growth hormone therapy: a pilot study.J Clin Sleep Med5(5):448-53 PMCID:PMC2762717

[79] Salehi P,Glass RP.Silent aspiration in infants with Prader-Willi syndrome identified by videofluoroscopic swallow study.Medicine (Baltimore)2017;96:e9256 PMCID:PMC5815776

[80] Katz-Salamon M,Cohen G.The effect of growth hormone on sleep-related cardio-respiratory control in Prader-Willi syndrome.Acta Paediatr2012;101:643-8

[81] Lindgren AC,Ritzén EM.Growth hormone treatment increases CO₂ response, ventilation and central inspiratory drive in children with Prader-Willi syndrome.Eur J Pediatr1999;158:936-40

[82] Giesecke J,Petersson M.Comorbidities, Endocrine medications, and mortality in Prader-Willi syndrome-a Swedish register study.J Clin Med2025;14:1307 PMCID:PMC11856969

[83] Greenberg F,Ledbetter DH.Neonatal diagnosis of Prader-Willi syndrome and its implications.Am J Med Genet1987;28:845-56

[84] Gunay-Aygun M,Heeger S,Cassidy SB.The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria.Pediatrics2001;10:E92

[85] Zhang M,Li H.Use of the MS-MLPA assay in prenatal diagnosis of Prader-Willi syndrome with mosaic trisomy 15.Taiwan J Obstet Gynecol2024;63:81-4

[86] Godler DE,Gamage D.Feasibility of screening for chromosome 15 imprinting disorders in 16, 579 newborns by using a novel genomic workflow.JAMA Netw Open2022;5:e2141911 PMCID:PMC8728620

[87] Paluoja P,Teder H.BinDel: detecting clinically relevant fetal genomic microdeletions using low-coverage whole-genome sequencing-based NIPT.Prenat Diagn2025;45:352-61

[88] Bohonowych J,McCandless SE.The global Prader-Willi Syndrome registry: development, launch, and early demographics.Genes (Basel)2019;10:713 PMCID:PMC6770999

[89] Miller JL,Bridges N.DESTINY PWS InvestigatorsDiazoxide choline extended-release tablet in people with Prader-Willi syndrome: a double-blind, placebo-controlled trial.J Clin Endocrinol Metab2023;108:1676-85 PMCID:PMC10271219

[90] Miller JL,Bridges N.C601/C602 InvestigatorsDiazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study.Obesity (Silver Spring)2024;32:252-61

[91] Beavers KM,Foy CM.GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials.Obesity (Silver Spring)2025;33:225-37 PMCID:PMC11774015

[92] Sinaud S,Bayle G.Diazoxide-induced insulin deficiency greatly reduced muscle protein synthesis in rats: involvement of eIF4E.Am J Physiol1999;276:E50-61

[93] Forbes GB.Perspectives on body composition.Curr Opin Clin Nutr Metab Care2002;5:25-30

[94] Seong EJ,Su ZY,Lee JH.Combined treatment of metformin and resveratrol promotes myogenesis through increased irisin release in C2C12 Cells.Pharm Res2025;42:419-28

[95] Hur KY.New mechanisms of metformin action: focusing on mitochondria and the gut.J Diabetes Investig2015;6:600-9 PMCID:PMC4627534

[96] Snyder DK,Clemmons DR.Persistent lipolytic effect of exogenous growth hormone during caloric restriction.Am J Med1995;98:129-34

[97] Rohm D,McCutcheon SR.Activation of the imprinted Prader-Willi syndrome locus by CRISPR-based epigenome editing.Cell Genom2025;5:100770 PMCID:PMC11872474